论文部分内容阅读
本刊讯欧洲药品管理局(EMA)药物警戒风险评估委员会(PRAC)近期完成了一项对含有抗组胺药羟嗪的安全性评估。此次评估是源于对大多数欧盟国家均出现的上述药品对心脏节律的潜在风险的担忧。含羟嗪的药品在欧盟的22个成员国以及挪威和冰岛通过国家程序获得许可。这些药品通常为口服,有时也可通过注射途径使用,存在不同的商品名,包括Atarax。不同国家批准的适应证存在较大差异,包括治疗焦虑症、缓解瘙痒症、作为
Benjamin The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Board (PRAC) recently completed a safety assessment of antihistamines containing hydroxyzines. The assessment is based on concerns that potential risks to heart rhythm from the above-mentioned drugs appear in most EU countries. Hydroxazine-containing medicines are licensed through national procedures in 22 EU member states as well as Norway and Iceland. These medicines are usually given orally and sometimes also by injection, and are available under different trade names, including Atarax. There are large differences in indications approved by different countries, including the treatment of anxiety disorders and pruritus, as